Redwood Pharma to participate in the NLS Days partner conference in Copenhagen
Stockholm, November 22, 2023. Redwood Pharma AB (publ) announces today that the company will participate in Nordic Life Science Days, the Nordics' largest investor and partnering meeting, at the end of November.
Redwood Pharma's CEO Martin Vidaeus will participate in the Nordic Life Science Days, NLS Days, organized at the Bella Center in Copenhagen, Denmark, between November 29-30. NLS Days is the Nordic region's leading partner event that brings together investors and companies in the life science industry from several different countries.
"Our focus is now on spreading knowledge about our innovative dry eye treatments and our drug delivery technology IntelliGel. We noted a strong interest in our programs during the BIO Europe partnering conference in Munich earlier in November and look forward to continuing dialogue with potential partners," says Redwood Pharma's CEO, Martin Vidaeus.
RP501 is being developed to be an effective and user-friendly treatment for dry eye, a disease that affects more than 300 million people around the world. RP501 is based on IntelliGel - a patented and unique formulation that has the consistency of a drop of water when instilled into the eye but immediately transforms into a viscous, protective and lubricating film that remains in the eye for a long time.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.com
About Redwood Pharma
Redwood Pharma AB (publ) (Nasdaq First North Growth Market: REDW) develops next-generation treatments for dry eye. More than 300 million people suffer from dry eyes and today's standard treatment provides only temporary relief and may need to be applied more than ten times a day. Redwood Pharma's programs are based on IntelliGel - a patented and unique formulation of polymers and water that has the consistency of a drop of water when dropped into the eye, where it immediately forms a viscous, protective and lubricating film that remains for a long time. The company is currently pursuing two development projects: RP501 as a readily available medical device for the first line treatment of dry eye, and the drug candidate RP101 that contains estrogen for the treatment of women who suffer from dry eye after menopause. The company’s Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm (+46 8 463 80 00, certifidadviser@penser.se). For more information, visit www.redwoodpharma.com